Long-Term Safety and Efficacy of Rilonacept in Patients With Systemic Juvenile Idiopathic Arthritis

The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis

(2012) Dirk Holzinger et al.   ANNALS OF THE RHEUMATIC DISEASES

A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features

(2011) Nicolino Ruperto et al.   ARTHRITIS AND RHEUMATISM

Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions

(2011) Elizabeth D. Mellins et al.   Nature Reviews Rheumatology

2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features

(2011) Timothy Beukelman et al.   ARTHRITIS CARE & RESEARCH

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

(2010) P. Quartier et al.   ANNALS OF THE RHEUMATIC DISEASES

Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: Report of forty-six patients from an international multicenter series

(2010) Peter A. Nigrovic et al.   ARTHRITIS AND RHEUMATISM

The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study

(2009) R Terkeltaub et al.   ANNALS OF THE RHEUMATIC DISEASES

The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1β form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis

(2009) Michael Frosch et al.   ARTHRITIS AND RHEUMATISM

Development and validation of a composite disease activity score for juvenile idiopathic arthritis

(2009) Alessandro Consolaro et al.   ARTHRITIS AND RHEUMATISM

Anakinra for Systemic Juvenile Arthritis

(2009) Andrew Zeft et al.   JCR-JOURNAL OF CLINICAL RHEUMATOLOGY

In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes

(2009) Helen J. Lachmann et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The Risk of Infections with Biologic Therapies for Rheumatoid Arthritis

(2009) Daniel E. Furst   SEMINARS IN ARTHRITIS AND RHEUMATISM

The pattern of response to anti–interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis

(2008) Marco Gattorno et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: Results from two sequential placebo-controlled studies

(2008) Hal M. Hoffman et al.   ARTHRITIS AND RHEUMATISM

Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study

(2008) Norman Ilowite et al.   CLINICAL RHEUMATOLOGY

Improving the evidence base for treatment of juvenile idiopathic arthritis: the challenge and opportunity facing the MCRN/ARC Paediatric Rheumatology Clinical Studies Group

(2008) J. Thornton et al.   RHEUMATOLOGY